Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.
News ReleasesAugust 24, 2022
HVTN at the 24th International AIDS Conference in Montreal

HVTN at the 24th International AIDS Conference in Montreal

HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more
News ReleasesJuly 28, 2022

News on HVTN

Read MORE
A promising HIV vaccine candidate gets a little help New strategy stirs a robust response from T cells tracked by McElrath lab May 24, 2023
Year in Pictures: 2022 A look back at the year through compelling images December 12, 2022
Could a 100-year-old TB vaccine help scientists find a better one? Harmless vaccine BCG is made of living bacteria; in tests might serve as a proxy for deadly tuberculosis December 12, 2022
Dr. Larry Corey receives Alexander Fleming Award Virologist honored by peers for his lifetime achievements against infectious diseases October 21, 2022